Do analysts rate TELO or HOWL?

Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 826.61%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Telomir Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Werewolf Therapeutics 1 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.14

Is TELO or HOWL more profitable?

Telomir Pharmaceuticals' return on equity of -98.73% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Telomir Pharmaceuticals N/A -98.73% -85.85% Werewolf Therapeutics N/A -166.99% -59.88%

Is HOWL or GANX more profitable?

Gain Therapeutics' return on equity of -161.59% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -166.99% -59.88% Gain Therapeutics N/A -161.59% -118.36%

Is HOWL or CYPH more profitable?

Cypherpunk Technologies' return on equity of -20.76% beat Werewolf Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -166.99% -59.88% Cypherpunk Technologies N/A -20.76% -19.48%

Werewolf Therapeutics (HOWL) Competitors

$0.40 +0.02 (+4.84%)

Closing price 04:00 PM Eastern

Extended Trading

$0.40 +0.00 (+0.07%)

As of 07:34 PM Eastern

Compare

HOWL vs. TELO, ATRA, SERA, GANX, and CYPH

Should you buy Werewolf Therapeutics stock or one of its competitors? Werewolf Therapeutics's main competitors and comparable companies include Telomir Pharmaceuticals (TELO), Atara Biotherapeutics (ATRA), Sera Prognostics (SERA), Gain Therapeutics (GANX), and Cypherpunk Technologies (CYPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Werewolf Therapeutics compare to Telomir Pharmaceuticals?

Telomir Pharmaceuticals (NASDAQ:TELO) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

Werewolf Therapeutics has a consensus target price of $3.75, indicating a potential upside of 826.61%. Given Werewolf Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Werewolf Therapeutics is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

Telomir Pharmaceuticals has higher earnings, but lower revenue than Werewolf Therapeutics. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A
Werewolf Therapeutics	$1.88M	10.46	-$60.82M	-$0.76	N/A

Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

In the previous week, Telomir Pharmaceuticals had 6 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 7 mentions for Telomir Pharmaceuticals and 1 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.87 beat Telomir Pharmaceuticals' score of 0.01 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Neutral
Werewolf Therapeutics	Very Positive

Telomir Pharmaceuticals' return on equity of -98.73% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-98.73%	-85.85%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

64.8% of Werewolf Therapeutics shares are owned by institutional investors. 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Werewolf Therapeutics beats Telomir Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Atara Biotherapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

In the previous week, Atara Biotherapeutics had 6 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 7 mentions for Atara Biotherapeutics and 1 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.87 beat Atara Biotherapeutics' score of -0.33 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Werewolf Therapeutics	Very Positive
Atara Biotherapeutics	Neutral

Werewolf Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -269.42%. Atara Biotherapeutics' return on equity of -79.12% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Atara Biotherapeutics	-269.42%	-79.12%	-73.01%

Atara Biotherapeutics has higher revenue and earnings than Werewolf Therapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	10.46	-$60.82M	-$0.76	N/A
Atara Biotherapeutics	$120.77M	0.60	$32.69M	-$0.67	N/A

Werewolf Therapeutics presently has a consensus price target of $3.75, suggesting a potential upside of 826.61%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential upside of 17.43%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Werewolf Therapeutics is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Werewolf Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market.

Summary

Werewolf Therapeutics beats Atara Biotherapeutics on 8 of the 15 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Sera Prognostics?

Sera Prognostics (NASDAQ:SERA) and Werewolf Therapeutics (NASDAQ:HOWL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Sera Prognostics currently has a consensus price target of $5.50, suggesting a potential upside of 180.61%. Werewolf Therapeutics has a consensus price target of $3.75, suggesting a potential upside of 826.61%. Given Werewolf Therapeutics' higher possible upside, analysts clearly believe Werewolf Therapeutics is more favorable than Sera Prognostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14

In the previous week, Sera Prognostics had 7 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 8 mentions for Sera Prognostics and 1 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.87 beat Sera Prognostics' score of -0.16 indicating that Werewolf Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sera Prognostics	Neutral
Werewolf Therapeutics	Very Positive

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 64.8% of Werewolf Therapeutics shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 23.6% of Werewolf Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Werewolf Therapeutics has a net margin of 0.00% compared to Sera Prognostics' net margin of -47,475.72%. Sera Prognostics' return on equity of -46.71% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-47,475.72%	-46.71%	-34.06%
Werewolf Therapeutics	N/A	-166.99%	-59.88%

Sera Prognostics has higher earnings, but lower revenue than Werewolf Therapeutics. Sera Prognostics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	959.42	-$31.93M	-$0.65	N/A
Werewolf Therapeutics	$1.88M	10.46	-$60.82M	-$0.76	N/A

Sera Prognostics has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market. Comparatively, Werewolf Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

Summary

Sera Prognostics beats Werewolf Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Gain Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Gain Therapeutics (NASDAQ:GANX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Werewolf Therapeutics has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Gain Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market.

Werewolf Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 826.61%. Gain Therapeutics has a consensus price target of $7.50, indicating a potential upside of 253.77%. Given Werewolf Therapeutics' higher probable upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Gain Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Gain Therapeutics had 8 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 9 mentions for Gain Therapeutics and 1 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.87 beat Gain Therapeutics' score of 1.01 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Werewolf Therapeutics	Very Positive
Gain Therapeutics	Positive

Gain Therapeutics has lower revenue, but higher earnings than Werewolf Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Werewolf Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	10.46	-$60.82M	-$0.76	N/A
Gain Therapeutics	$50K	1,850.34	-$20.16M	-$0.58	N/A

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 12.0% of Gain Therapeutics shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by company insiders. Comparatively, 4.2% of Gain Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Gain Therapeutics' return on equity of -161.59% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Gain Therapeutics	N/A	-161.59%	-118.36%

Summary

Werewolf Therapeutics and Gain Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Werewolf Therapeutics (NASDAQ:HOWL) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership.

Cypherpunk Technologies has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Cypherpunk Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	10.46	-$60.82M	-$0.76	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	$0.56	1.15

Cypherpunk Technologies' return on equity of -20.76% beat Werewolf Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Cypherpunk Technologies	N/A	-20.76%	-19.48%

64.8% of Werewolf Therapeutics shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 23.6% of Werewolf Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Werewolf Therapeutics currently has a consensus price target of $3.75, indicating a potential upside of 826.61%. Cypherpunk Technologies has a consensus price target of $0.90, indicating a potential upside of 39.75%. Given Werewolf Therapeutics' higher probable upside, analysts clearly believe Werewolf Therapeutics is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.14
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Cypherpunk Technologies had 5 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 6 mentions for Cypherpunk Technologies and 1 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.87 beat Cypherpunk Technologies' score of 0.55 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Werewolf Therapeutics	Very Positive
Cypherpunk Technologies	Positive

Werewolf Therapeutics has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of 0.09, meaning that its stock price is 91% less volatile than the broader market.

Summary

Werewolf Therapeutics and Cypherpunk Technologies tied by winning 7 of the 14 factors compared between the two stocks.

Get Werewolf Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOWL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOWL vs. The Competition

Export

Metric	Werewolf Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.76M	$3.71B	$6.98B	$13.04B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	N/A	10.68	269.86	25.30
Price / Sales	10.46	1,308.25	601.81	101.06
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	1.19	17.49	13.08	6.33
Net Income	-$60.82M	-$13.32M	$3.45B	$347.70M
7 Day Performance	1.91%	1.74%	1.12%	1.07%
1 Month Performance	17.61%	1.60%	1.79%	1.03%
1 Year Performance	-69.34%	56.43%	67.69%	20.77%

Werewolf Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOWL Werewolf Therapeutics	3.1524 of 5 stars	$0.40 +4.8%	$3.75 +826.6%	-71.4%	$18.76M	$1.88M	N/A	40	Positive News Gap Up
TELO Telomir Pharmaceuticals	0.5321 of 5 stars	$1.15 -7.3%	N/A	-34.4%	$79.10M	N/A	N/A	1	News Coverage Earnings Report
ATRA Atara Biotherapeutics	1.9376 of 5 stars	$8.77 +2.6%	$9.50 +8.3%	-29.8%	$79.02M	$23.14M	N/A	330	Earnings Report Gap Up
SERA Sera Prognostics	2.6754 of 5 stars	$1.93 -8.1%	$5.50 +185.0%	-12.6%	$75.58M	$80K	N/A	120	News Coverage Earnings Report
GANX Gain Therapeutics	2.8247 of 5 stars	$1.76 +0.6%	$7.50 +326.1%	+39.4%	$75.06M	$50K	N/A	20	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOWL) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. TELO, ATRA, SERA, GANX, and CYPH

How does Werewolf Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Werewolf Therapeutics compare to Atara Biotherapeutics?

Summary

How does Werewolf Therapeutics compare to Sera Prognostics?

Summary

How does Werewolf Therapeutics compare to Gain Therapeutics?

Summary

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Werewolf Therapeutics (HOWL) Competitors

HOWL vs. TELO, ATRA, SERA, GANX, and CYPH

How does Werewolf Therapeutics compare to Telomir Pharmaceuticals?

Do analysts rate TELO or HOWL?

Which has higher earnings & valuation, TELO or HOWL?

Which has more volatility and risk, TELO or HOWL?

Does the media refer more to TELO or HOWL?

Is TELO or HOWL more profitable?

Do institutionals & insiders have more ownership in TELO or HOWL?

Summary

How does Werewolf Therapeutics compare to Atara Biotherapeutics?

Does the media prefer HOWL or ATRA?

Is HOWL or ATRA more profitable?

Which has better valuation & earnings, HOWL or ATRA?

Do analysts rate HOWL or ATRA?

Do institutionals & insiders hold more shares of HOWL or ATRA?

Which has more volatility and risk, HOWL or ATRA?

Summary

How does Werewolf Therapeutics compare to Sera Prognostics?

Do analysts prefer SERA or HOWL?

Does the media favor SERA or HOWL?

Do insiders and institutionals have more ownership in SERA or HOWL?

Is SERA or HOWL more profitable?

Which has better earnings & valuation, SERA or HOWL?

Which has more risk & volatility, SERA or HOWL?

Summary

How does Werewolf Therapeutics compare to Gain Therapeutics?

Which has more volatility and risk, HOWL or GANX?

Do analysts recommend HOWL or GANX?

Does the media prefer HOWL or GANX?

Which has better earnings & valuation, HOWL or GANX?

Do insiders & institutionals believe in HOWL or GANX?

Is HOWL or GANX more profitable?

Summary

How does Werewolf Therapeutics compare to Cypherpunk Technologies?

Which has stronger valuation and earnings, HOWL or CYPH?

Is HOWL or CYPH more profitable?

Do institutionals & insiders believe in HOWL or CYPH?

Do analysts prefer HOWL or CYPH?

Does the media prefer HOWL or CYPH?

Which has more volatility & risk, HOWL or CYPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL vs. The Competition

Werewolf Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools